Capricor's Novel Stem Cell Therapy is a Potential Multi-Billion Dollar Market

Share Article

Capricor, Inc. presented at the 10th SoCalBio Investor Conference its mission to revolutionize the treatment of heart disease with novel cardiac stem cell therapy and capture a potential multi-billion market.

Oliver Foellmer, President and CEO, Capricor Inc. (http://www.capricor.com), presented the company's mission to revolutionize the treatment of heart disease with novel cardiac stem cell therapy and capture a multi-billion dollar market at the Southern California BioMedical Council (SoCalBio or SCBC) 10th Investor Conference, held at the Wilshire Grand Hotel in Los Angeles, California.

The Southern California BioMedical Council Conference showcases emerging biotech and device companies from Southern California seeking funding and partnerships. Capricor's presentation, entitled "Heart to Heart: Cardiac Stem Cells for Heart Attack and Heart Failure," highlights the urgent medical need for the 1.2 million U.S. heart attack patients per year, the Cardiosphere-derived Stem Cells or CDC technology, and the multi-billion dollar market potential for Capricor's heart therapies.

"CDCs are the perfect stem cells to treat heart attacks and chronic heart failure," said Foellmer. "Our stem cells are easily accessible from the patient themselves, readily grown in large numbers, and have proven themselves extremely safe. Unlike embryonic stem cells, there are no ethical or moral quandaries. And unlike other adult stem cells, such as bone marrow stem cells, our CDCs actually regrow cardiac muscle and vasculature. In short, CDCs have great potential for patients with a recent heart attack or chronic heart failure and we eagerly look forward to our imminent clinical trials."

Capricor Inc., headquartered in Los Angeles, California, is a leading biotechnology company that specializes in discovering, developing, and commercializing biotherapeutics for the treatment of heart diseases. Capricor's mission is to revolutionize the treatment of cardiac disease by translating novel stem cell science into therapeutics that halt and reverse the disease process for patient's, their families, and society in general. Please visit http://www.capricor.com for more information.

The Southern California Biomedical Council is the trade association of the life-science industry in Greater Los Angeles. The mission of SoCalBio is to represent and promote medical device and biotechnology industry in Los Angeles and Orange Counties as well as adjacent communities in the Inland Empire and Gold Coast. Visit http://www.socalbio.org for more information.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Kelly Rice
Capricor
310.601.4377
Email >
Visit website